Literature DB >> 11971085

MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

R J Killiany1, B T Hyman, T Gomez-Isla, M B Moss, R Kikinis, F Jolesz, R Tanzi, K Jones, M S Albert.   

Abstract

BACKGROUND: MRI measures of the entorhinal cortex and the hippocampus have been used to predict which nondemented individuals with memory problems will progress to meet criteria for AD on follow-up, but their relative accuracy remains controversial.
OBJECTIVES: To compare MRI measures of the entorhinal cortex and the hippocampus for predicting who will develop AD.
METHODS: MRI volumes of the entorhinal cortex and the hippocampus were obtained in 137 individuals comprising four groups: 1) individuals with normal cognition both at baseline and after 3 years of follow-up (n = 28), 2) subjects with memory difficulty but not dementia both at baseline and after 3 years of follow-up (n = 73), 3) subjects with memory difficulty at baseline who were diagnosed with probable AD within 3 years of follow-up (n = 21), and 4) patients with mild AD at baseline (n = 16).
RESULTS: Measures of both the entorhinal cortex and the hippocampus were different for each of the pairwise comparisons between the groups (p < 0.001) and were correlated with tests of memory (p < 0.01). However, the volume of the entorhinal cortex differentiated the subjects from those destined to develop dementia with considerable accuracy (84%), whereas the measure of the hippocampus did not.
CONCLUSION: These findings are consistent with neuropathologic data showing substantial involvement of the entorhinal cortex in the preclinical phase of AD and suggest that, as the disease spreads, atrophic change develops within the hippocampus, which is measurable on MRI.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  2002        PMID: 11971085     DOI: 10.1212/wnl.58.8.1188

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  172 in total

Review 1.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults.

Authors:  Deepti Putcha; Michael Brickhouse; Kelly O'Keefe; Caroline Sullivan; Dorene Rentz; Gad Marshall; Brad Dickerson; Reisa Sperling
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 3.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

4.  Individual differences in neurocognitive aging of the medial temporal lobe.

Authors:  Michela Gallagher; Carlo Colantuoni; Howard Eichenbaum; Rebecca P Haberman; Peter R Rapp; Heikki Tanila; Iain A Wilson
Journal:  Age (Dordr)       Date:  2006-11-25

5.  Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume?

Authors:  Herve Lemaitre; Aaron L Goldman; Fabio Sambataro; Beth A Verchinski; Andreas Meyer-Lindenberg; Daniel R Weinberger; Venkata S Mattay
Journal:  Neurobiol Aging       Date:  2010-08-23       Impact factor: 4.673

6.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

7.  Short-Term Memory Depends on Dissociable Medial Temporal Lobe Regions in Amnestic Mild Cognitive Impairment.

Authors:  Sandhitsu R Das; Lauren Mancuso; Ingrid R Olson; Steven E Arnold; David A Wolk
Journal:  Cereb Cortex       Date:  2015-02-27       Impact factor: 5.357

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

9.  Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size.

Authors:  Peng Yu; Jia Sun; Robin Wolz; Diane Stephenson; James Brewer; Nick C Fox; Patricia E Cole; Clifford R Jack; Derek L G Hill; Adam J Schwarz
Journal:  Neurobiol Aging       Date:  2013-10-03       Impact factor: 4.673

10.  MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD.

Authors:  S George; E J Mufson; S Leurgans; R C Shah; C Ferrari; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2009-12-14       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.